|Videos|December 22, 2019
Treating HER2-Positive Metastatic Breast Cancer: DESTINY-Breast02 and DESTINY-Breast03
Author(s)Sponsored Content
The role of antibody drug conjugate DS-8201a (trastuzumab deruxtecan) in the treatment of HER2-positive metastatic breast cancer and an overview of the DESTINY-Breast02 and DESTINY-Breast03 trials.
Advertisement
The role of antibody drug conjugate DS-8201a (trastuzumab deruxtecan) in the treatment of HER2-positive metastatic breast cancer and an overview of the DESTINY-Breast02 and DESTINY-Breast03 trials.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
Balance Exercises for Patients With Cancer: How the Single-Leg Stand Builds Stability
2
Wildfire Smoke and Cancer Risk: What Patients Should Know
3
Clock Touches: An Advanced Balance Exercise for Patients with Cancer
4
A New Chapter in Prostate Cancer Care: How Focal Cryotherapy Is Changing the Game
5